RODALLEC, Anne; SICARD, Guillaume; FANCIULLINO, Raphaelle; BENZEKRY, Sébastien; LACARELLE, Bruno; MILANO, Gérard; CICCOLINI, Joseph

doi:10.1080/17425255.2018.1540588

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

RODALLEC, Anne
Simulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]

SICARD, Guillaume
Simulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]

FANCIULLINO, Raphaelle
Simulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]

Langue

Article de revue

Ce document a été publié dans

Expert Opinion on Drug Metabolism and Toxicology. 2018-10-24, vol. 14, n° 11, p. 1-9

Taylor & Francis

Résumé en anglais

Immune checkpoint inhibitors have considerably changed the landscape of oncology. However apart from world-acclaimed success stories limited to melanoma and lung cancer, many solid tumors failed to respond to immune checkpoint inhibitors due to limited immunogenicity, unfavorable tumor micro-environments (TME), lack of infiltrating T lymphocytes or increases in Tregs. Areas covered: Combinatorial strategies are foreseen as the future of immunotherapy and using cytotoxics or modulating agents is expected to boost the efficacy of immune checkpoint inhibitors. In this respect, nanoparticles displaying unique pharmacokinetic features such as tumor targeting properties, optimal payload delivery and long-lasting interferences with TME, are promising candidates for such combinations. This review covers the basis, expectancies, limits and pitfalls of future combination between nanoparticles and immune check point inhibitors. Expert opinion: Nanoparticles allow optimal delivery of variety of payloads in tumors while sparing healthy tissue, thus triggering immunogenic cell death. Depleting tumor stroma could further help immune cells and monoclonal antibodies to better circulate in the TME, plus immune-modulating properties of the charged cytotoxics. Finally, nanoparticles themselves present immunogenicity and antigenicity likely to boost immune response at the tumor level.< Réduire

Mots clés en anglais

Immunotherapy

nanoparticles

immunogenicity

drug delivery

pharmacokinetics

cancer

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Origine

Unités de recherche